Memorial Sloan Kettering Cancer Center

Columbia University

Universiteit Gent

Ghent University

Elisa Oricchio

Adolfo A Ferrando

Hans Guido Wendel

Hans-Guido Wendel

Teresa Palomero

Andrew L Wolfe

Konstantinos John Mavrakis

Kim De Keersmaecker

Franki Speleman

Pieter Van Vlierberghe

Peter Van Vlierberghe

The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagonists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.

Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.

Methods for treatment of lymphomas with mutations in cell cycle genes

Growing community of inventors

New York, NY, United States of America

Elisa Oricchio